Patient preferences for oropharyngeal cancer treatment de-escalation

Head and Neck

Volumn 35, Issue 2, 2013, Pages 151-159

  Brotherston, Drew C ^a,b   Poon, Ian ^a,b   Le, Tuyen ^a,b   Leung, Martin ^a,b   Kiss, Alex ^c   Ringash, Jolie ^b,d   Balogh, Judith ^a,b   Lee, Justin ^a,b   Wright, James R ^e,f  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

deintensification; HPV; oropharynx; preferences; trade off

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE REDUCTION; RADIATION INJURY; SEMI STRUCTURED INTERVIEW; SURVIVAL RATE; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OROPHARYNGEAL NEOPLASMS; PATIENT PREFERENCE; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872782456     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22930     Document Type: Article

References (54)

1. Lo TC, Wiley AL Jr, Ansfield FJ, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol 1976; 126: 229-235.
2. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
3. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
4. Jo S, Juhasz A, Zhang K, et al. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 2009; 29: 1467-1474.
5. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14.
6. Kumar B, Cordell KG, Lee JS, et al. EGFR, p 16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
7. Lassen P,. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010; 95: 371-380.
8. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 140: 228-234.
9. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071-1077.
10. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009; 2: 776-781.
11. Tribius S, Ihloff AS, Rieckmann T, Petersen C, Hoffmann M,. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 2011; 304: 71-79.
12. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 3138-3146.
13. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
14. Bahl M, Siu LL, Pond GR, et al. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys 2004; 60: 1127-1136.
15. Beaver ME, Matheny KE, Roberts DB, Myers JN,. Predictors of weight loss during radiation therapy. Otolaryngol Head Neck Surg 2001; 125: 645-648.
16. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
17. List MA, Bilir SP,. Functional outcomes in head and neck cancer. Semin Radiat Oncol 2004; 14: 178-189.
18. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999; 17: 1020-1028.
19. Tan EH, Chua ET, Wee J, et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 1999; 45: 597-601.
20. Cassileth BR,. Clinical trials: time for action. J Clin Oncol 2003; 21: 765-766.
21. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728-1733.
22. Wright JR, Whelan TJ, Schiff S, et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol 2004; 22: 4312-4318.
23. Bremnes RM, Andersen K, Wist EA,. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 1995; 31A: 1955-1959.
24. Brundage MD, Davidson JR, Mackillop WJ, Feldman-Stewart D, Groome P,. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making 1998; 18: 256-267.
25. Duric V, Stockler M,. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol 2001; 2: 691-697.
26. Hirose T, Horichi N, Ohmori T, et al. Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 2005; 44: 107-113.
27. Hirose T, Yamaoka T, Ohnishi T, et al. Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psychooncology 2009; 18: 483-489.
28. Koedoot CG, de Haan RJ, Stiggelbout AM, et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. Br J Cancer 2003; 89: 2219-2226.
29. Matsuyama R, Reddy S, Smith TJ,. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006; 24: 3490-3496.
30. Mazur DJ, Hickman DH,. Patient preferences: survival vs quality-of-life considerations. J Gen Intern Med 1993; 8: 374-377.
31. Silvestri G, Pritchard R, Welch HG,. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771-775.
32. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300: 1458-1460.
33. Singer S, Wollbruck D, Wulke C, et al. Validation of the EORTC QLQ-C30 and EORTC QLQ-H&N35 in patients with laryngeal cancer after surgery. Head Neck 2009; 31: 64-76.
34. Dales RE, O'Connor A, Hebert P, Sullivan K, McKim D, Llewellyn-Thomas H,. Intubation and mechanical ventilation for COPD: development of an instrument to elicit patient preferences. Chest 1999; 116: 792-800.
35. Harrison JD, Solomon MJ, Young JM, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg 2008; 143: 389-394.
36. Llewellyn-Thomas HA,. Investigating patients' preferences for different treatment options. Can J Nurs Res 1997; 29: 45-64.
37. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD,. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making 1996; 16: 262-282.
38. Palda VA, Llewellyn-Thomas HA, Mackenzie RG, Pritchard KI, Naylor CD,. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol 1997; 15: 3192-3200.
39. Kennedy ED, Schmocker S, Victor C, et al. Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? Cancer 2011; 117: 2853-2862.
40. Litwin MS, McGuigan KA,. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999; 17: 2882-2888.
41. Fried TR, O'Leary J, Van Ness P, Fraenkel L,. Inconsistency over time in the preferences of older persons with advanced illness for life-sustaining treatment. J Am Geriatr Soc 2007; 55: 1007-1014.
42. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J,. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010; 94: 30-35.
43. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007; 8: 613-624.
44. Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; 1: 967-972.
45. Yeoh KW, Mikhaeel NG,. Role of radiotherapy in modern treatment of Hodgkin's lymphoma. Adv Hematol 2011; 2011: 258797.
46. Vena D, Poon I, Kusano M, et al. A preliminary analysis to assess intra-treatment FDG-PET parameters that predict for locoregional control in advanced head and neck cancer treated with chemoradiation. Int J Radiat Oncol Biol Phys 2009; 75: S422.
47. Vena D, Poon I, Kusano M, et al. Intra-treatment FDG positron emission tomography responses assessment of advanced head and neck cancer treated with radiation +/- chemotherapy. Radiother Oncol 2010; 94: S28.
48. Schroen AT, Petroni GR, Wang H, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010; 7: 312-321.
49. Donovan JL, Lane JA, Peters TJ, et al. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol 2009; 62: 29-36.
50. Wade J, Donovan JL, Lane JA, Neal DE, Hamdy FC,. It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. Soc Sci Med 2009; 68: 2018-2028.
51. Fried TR, Bradley EH, Towle VR,. Assessment of patient preferences: integrating treatments and outcomes. J Gerontol B Psychol Sci Soc Sci 2002; 57: S348-S354.
52. Badia X, Herdman M, Kind P,. The influence of ill-health experience on the valuation of health. Pharmacoeconomics 1998; 13: 687-696.
53. Kind P, Dolan P,. The effect of past and present illness experience on the valuations of health states. Med Care 1995; 33 (4 Suppl): AS255-AS263.
54. Lindley C, Vasa S, Sawyer WT, Winer EP,. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998; 16: 1380-1387.